Category Archives: Molecular Medicine

Researchers say they've found a system in the human heart that allows the organ to restart itself. Their discovery could lead to the replacement of pacemakers.

In an episode of Star Trek: The Next Generation, Lt. Worf is badly injured, but recovers when it is discovered that his body holds a lot of redundant parts and organs for example, 23 ribs that allow him to regenerate.

Science fiction?

Not entirely.

A team of researchers at The Ohio State University Wexner Medical Center discovered that the human heart contains its own fail-safe backup battery system to regulate the heartbeat.

Their findings were published in Science Translational Medicine.

If further testing is successful, fewer people might need mechanical pacemakers in the future.

The potential market is big.

More than 200,000 people in the United States have a pacemaker implanted every year.

The research is still preliminary, but scientists hope to turn it into practical use some day.

In the future we want to develop something that practitioners would welcome, Vadim Fedorov, PhD, an associate professor of physiology and cell biology at The Ohio State University College of Medicine, told Healthline.

Fedorov explained that an implanted pacemaker works by replacing the hearts defective natural pacemaker functions.

The sinoatrial (SA) node, or sinus node, is the heart's natural pacemaker. It's a small mass of specialized cells in the top of the right atrium (upper chamber of the heart). It produces the electrical impulses that cause the heart to beat.

The heart is hardwired to maintain consistency. Irregular heartbeat, or arrhythmia, can be due to heart disease or other problems, such as changes in diet or hormones or electrolyte imbalance.

Optical and molecular mapping of the human heart revealed that the SA node is home to multiple pacemakers, specialized cardiomyocytes that generate electrical heartbeat-inducing impulses.

Total cardiac arrest occurs only when all pacemakers and conduction pathways fail.

Too technical?

Think of it as a car battery. One day your car wont start. Turns out the battery is still good, but one of the connector cables is bad.

So you clean or replace the wire and save yourself from major repairs.

The Ohio State teams discovery showed that the human heart battery restarts itself.

To prove their point, the researchers actually restarted hearts that were destined for the trash heap.

Most of them came from people getting new hearts or accident victims whose hearts were not suitable for transplant.

We kept them in a special solution, he said. When we warm them to body temperature, they will beat.

The discovery, while exciting, is not going to change clinical practice in the next 60 days.

But it offers promise.

Dr. John Hummel, FACC, is a cardiologist at The Ohio State University Wexner Medical Center and is director of the electrophysiology research section and professor of cardiovascular medicine.

He told Healthline the study is intriguing.

These findings finally give us insight as to the actual structure and behavior of the natural pacemaker of the human heart, he said. Diagnosing disease of the natural pacemaker is often straightforward, but can also be one of the more challenging diagnoses to make.

Dr. Fedorovs findings will likely allow us to develop new approaches to discriminate disease from normal behavior of the sinus node, and give our patients a definitive diagnosis of health or disease of the hearts natural pacemaker, Hummel explained.

Funding to translation of this bench research to clinic research is the next step, he added.

Dr. Gordon Tomaselli, professor of medicine, cellular and molecular medicine at the Johns Hopkins School of Medicine and past president of the American Heart Association, expressed similar thoughts.

The work by Vadim Fedorovs group is a beautifully done study on explanted [not used for transplant] human hearts, Tomaselli told Healthline.

He called the infrared optical mapping studies with pharmacological interventions demonstrating the functional redundancy and complexity of the sinoatrial node (SAN) the most compelling part of the work.

Being able to view the hearts in three dimensions increases the researchs usefulness.

Tomaselli pointed out that researchers have known for decades from previous work in animals, and in clinical human electrophysiological labs, that SAN is functionally redundant and anatomically complex.

He urged caution.

I do not think this paper will fundamentally change the management of patients with regard to pacemaker implantation, he said. Although around half of pacemakers are implanted for diseases of the sinus node or atrium, they are implanted not to prolong life but instead to relieve symptoms [fatigue, shortness of breath particularly with exercise].

He went on, The more life-threatening problems with electrical conduction in the heart for which we put in pacemakers to prolong life involve the electrical system that connects the top and bottom chamber [called the AV node] and the conduction system in the lower chambers. This paper does not address this problem.

So, for the meantime, a Klingon skeleton might be your best bet.

Read this article:
The Human Heart May Have a Natural 'Backup Battery' - Healthline

More than 300,000 students return to college and university campuses this month in Georgia.

The biggest changes include a newcampus carry law that allows students with licensed weapons permits to carry firearms on portions of campuses, additional credit to studentswho take approved STEM courses to keep their HOPE scholarships and the repurposing of Turner Field into Georgia States new football stadium.

Heres a look at some changes at some of metro Atlantas largest campuses and the University of Georgia.

The renovation of Rebekah Scott Hall. The $16.5 million project will house a new welcome center, updated offices for admissions and financial aid and residential space for students who will live on the upper two floors.

Atlanta Metropolitan State College

An online Bachelor of Science degree in organizational leadership. It includes a choice of concentration in public service, healthcare administration or office administration and technology.

Its createdthe Department of Cyber-Physical Systems. It will include new bachelor of science programs in cybersecurity, robotics, and data analytics.

The first-two floors of a new $400 million hospital tower opened on July 31, bringing the total number of licensed beds at Emory University Hospital to 733. Patient floors begin opening in late August, and the hospital tower will be fully operational by the end of October.

Awidening of a portion of Clifton Road and its sidewalks, a bike lane, new landscaping and improved visibility of intersections along Clifton Road.

The campus West Village, which includes five micro-restaurants, Panera Bread and Starbucks, music classrooms, and shared meeting rooms.

Georgia Techs West Village, which will include shops, restaurants, classrooms and meeting rooms. PHOTO CONTRIBUTED

The new football stadium, which will have its first game on Aug. 31 against Tennessee State.

A new College of the Arts that offers 20 top undergraduate, graduate and non-degree programs in art, design, music, film, digital media, theater, etc.

New building for its growing Creative Media Industries Initiative.

Kennesaw State University

Students applying to KSU for fall 2018 can choose to apply through a non-binding, early action application or through a regular decision application, a process used by most competitive universities in the state. Meeting the minimum requirements will no longer guarantee a spot at the university.

New degree programs in computer engineering and cybersecurity.

The college is expanding its health science classes. For the first time, classes in human anatomy, microbiology and ethnobotany will be offered this fall to attract more students interested in pursuing careers as dentists, pharmacists, and medical doctors.

Interim president Harold Martin, a former valedictorian. The college is conducting a search process for a permanent president.

The university is breaking ground on the I.W.Ike Cousins for Science and Innovation. The center will have laboratory-classrooms, independent study labs, open study rooms and faculty offices.

The college has a new documentary filmmaking and photography majors beginning this fall. Both new majors are part of the Department of Art & Visual Culture, formerly the Department of Art & Art History.

In September, theyll open a facility to support the Center for Molecular Medicine. The state provided $17 million to support the project. The faculty for this center are working on cures and therapies for diseases such as diabetes, cancer and dementia.

Best quality of life: Emory University (No. 3), Agnes Scott College (No. 20) Great financial aid: Emory University (No. 15) Most conservative students: Berry College (No. 20) Most liberal students: Agnes Scott College (No. 12) Most LGBTQ-friendly: Agnes Scott College (No. 7) Lots of race/class interaction: Agnes Scott College (No. 20) Most beautiful campus: Berry College (No. 9) Most active student government: Agnes Scott College (No. 9) Best college dorms: Emory University (No. 8) Most religious students

See the original post:
Georgia colleges gear up for new semester - AJC.com - Atlanta Journal Constitution

The researchers discovered that the genetic activity of mouse skeletal muscles is particularly intense during the first two weeks after birth; a number of genes alter the amount of proteins produced, while other genes go through alternative splicing and produce different proteins.

Among the genes going through alternative splicing, those involved in calcium-handling functions predominated. Calcium is very important for skeletal and heart muscle because the influx of calcium into the cell stimulates contraction and other functions.

First author Dr. Amy Brinegar, who was a graduate student in the Cooper lab while she was working on this project and recently graduated from the doctoral program in molecular and cellular biology at Baylor, selected three calcineurin A genes, which are involved in calcium-handling functions, and reversed their natural process of alternative splicing in adult mouse muscles. Then, Dr. George Rodney, associate professor of molecular physiology at Baylor, and a graduate student in his lab, James Loehr, who are co-authors on this paper, determined the effect of switching back alternative splicing on functions of isolated adult mouse skeletal muscle in the lab.

They discovered that muscles in which the adult forms of the calcineurin A genes had been switched back to the newborn forms showed a change in calcium flow and were less strong than muscles that retained the adult forms of calcineurin A.

We showed that just by changing three of about 11,000 genes that are estimated to be expressed in adult mouse muscle, we were able to change physiological parameters of those muscles, said Brinegar. This work supports the growing evidence in favor of a physiological role of alternative splicing.

Importantly, about 50 percent of the genes we discovered to undergo alternative splicing are conserved, meaning that the genes go through the same changes both in mice and humans, which opens the possibility of modeling human muscle disorders in the mouse, Cooper said.

Other contributors top this work include Zheng Xia and Wei Li, both from Baylor.

Financial support was provided by National Institutes of Health grants R01AR045653, R01HL045565, R01AR060733, T32 HL007676, R01HG007538, R01CA193466 and R01AR061370. Further support was provided by the Muscular Dystrophy Association grant RG4205.

See original here:
Change in protein production essential to muscle function - Baylor College of Medicine News (press release)

By KIMBERLY HOUGHTONUnion Leader CorrespondentAugust 14. 2017 11:06PM

This sequence of images shows the development of embryos after being injected with a biological kit to edit their DNA, removing a genetic mutation known to cause hypertrophic cardiomyopathy.(Oregon Health & Science University)

Bryan Luikart, an associate professor of molecular and systems biology at Geisel School of Medicine at Dartmouth College.

It is pretty amazing. It is a super-exciting time to be a scientist right now, said Bryan Luikart, an associate professor of molecular and systems biology at Geisel School of Medicine at Dartmouth College.

The study, which was published in the journal Nature, was detailed in a New York Times report. According to the article, Oregon researchers reported they repaired dozens of human embryos, fixing a mutation that causes a common heart condition that can lead to sudden death later in life.

The way they have dodged some ethical considerations is that they didnt go on to have that embryo grow into a person, said Luikart, explaining that if the embryos with the repaired mutation did have the opportunity to develop, they would be free of the heart condition.

At the Geisel School of Medicine at Dartmouth, Luikart and his colleagues have already been using this concept with mouse embryos, focusing specifically on autism.

Researchers are using the gene-editing method called CRISPR-Cas9 in hopes of trying to more fully understand autism, which he said is the most critical step in eventually finding a cure.

I think the CRISPR is a tremendous breakthrough. The question really is where and when do you want to use it, Luikart said. I have no ethical concerns using it as a tool to better understand biology.

The new milestone, an example of human genetic engineering, does carry ethical concerns that Luikart said will trigger some debates. He acknowledged that while the advancement of gene-editing technology could eventually stop unwanted hereditary conditions, it also allows for creating babies with smarter, stronger or more attractive traits.

The ability to do that is now within our grasp more than it has ever been, he said.

More importantly, the breakthrough could ultimately eliminate diseases, Luikart said. As the technology advances, he said, genetic diseases that are passed down to children may be corrected before the child receives them.

He used another example of a brain tumor, which often returns after it is surgically removed. Now, once the brain tumor is removed, there is the possibility of placing something in the space to edit and fix the mutation that causes the brain tumor in the first place if physicians are able to find the right cell to edit, Luikart said.

People are definitely thinking along those lines, or cutting the HIV genome, said Luikart, who predicts that those advancements will occur in mice within the next decade, and the ability to do that in humans is definitely there.

The big question is whether that can occur without some sort of side effect that was not predicted, he said.

Columbia University Medical Center posted an article earlier this year warning that CRISPR gene editing can cause hundreds of unintended mutations, based on a study published recently in Nature Methods.

This past May, MilliporeSigma announced it has developed a new genome editing tool that makes CRISPR more efficient, flexible and specific, giving researchers more experimental options and faster results that can accelerate drug development and access to new therapies, according to a release.

CRISPR genome editing technology is advancing treatment options for some of the toughest medical conditions faced today, including chronic illnesses and cancers for which there are limited or no treatment options, states the release, adding the applications of CRISPR are far ranging from identifying genes associated with cancer to reversing mutations that cause blindness.

It is pretty big news, Luikart said.

khoughton@newstote.com

HealthHanover

The rest is here:
New Hampshire biologist reacts to gene-editing discovery - The Union Leader

Credit: CC0 Public Domain

Researchers have developed a more precise way of diagnosing suicide risk, by developing blood tests that work in everybody, as well as more personalized blood tests for different subtypes of suicidality that they have newly identified, and for different psychiatric high-risk groups.

The research team, led by scientists at the Indiana University School of Medicine, also showed how two apps, one based on a suicide risk checklist and the other on a scale for measuring feelings of anxiety and depression, work along with the blood tests to enhance the precision of tests and to suggest lifestyle, psychotherapeutic and other interventions. Lastly, they identified a series of medications and natural substances that could be developed for preventing suicide.

"Our work provides a basis for precision medicine and scientific wellness preventive approaches," said Alexander B. Niculescu III, MD, PhD, professor of psychiatry and medical neuroscience at IU School of Medicine and attending psychiatrist and research and development investigator at the Richard L. Roudebush Veterans Affairs Medical Center.

The article, "Precision medicine for suicidality: from universality to subtypes and personalization," appears in the August 15 online edition of the Nature Publishing Group's leading journal in psychiatry, Molecular Psychiatry.

The research builds on earlier studies from the Niculescu group.

"Suicide strikes people in all walks of life. We believe such tragedies can be averted. This landmark larger study breaks new ground, as well as reproduces in larger numbers of individuals some of our earlier findings," said Dr. Niculescu.

There were multiple steps to the research, starting with serial blood tests taken from 66 people who had been diagnosed with psychiatric disorders, followed over time, and who had at least one instance in which they reported a significant change in their level of suicidal thinking from one testing visit to the next. The candidate gene expression biomarkers that best tracked suicidality in each individual and across individuals were then prioritized using the Niculescu group's Convergent Functional Genomics approach, based on all the prior evidence in the field.

Next, working with the Marion County (Indianapolis, Ind.) Coroner's Office, the researchers tested the validity of the biomarkers using blood samples drawn from 45 people who had committed suicide.

The biomarkers were then tested in another larger, completely independent group of individuals to determine how well they could predict which of them would report intense suicidal thoughts or would be hospitalized for suicide attempts.

The biomarkers identified by the research are RNA molecules whose levels in the blood changed in concert with changes in the levels of suicidal thoughts experienced by the patients. Among the findings reported in the current paper were:

Explore further: Researchers identify objective predictors of suicidality in women

More information: Molecular Psychiatry (2017). DOI: 10.1038/mp.2017.128

Excerpt from:
Precision medicine opens the door to scientific wellness preventive approaches to suicide - Medical Xpress

Integrative Molecular Medicine (IMM) Online ISSN: 2056-6360 University College London Cancer Treatment Centers of America

Integrative Molecular Medicine (IMM) is a peer-reviewed, online open access journal dedicated to a new research discipline at the interface between clinical research and basic biology. We aim to publish articles that broadly enlighten the biomedicine research community by providing an insight on breakthrough discoveries in basic and clinical medicinal research, thereby lending a strong impetus to this important and rapidly developing field and helping to forge new links between clinicians and molecular biologists. Integrative Molecular Medicine highlights ongoing integrative basic and clinical biomedicines covering fields of biology and medicine.As such the following qualities are essential in any article published by the journal: scientific credibility and rigour, and coherence and clarity in the writing. Contributions do not need to be novel as confirmatory and replication studies will be considered, however the article must present new findings, which could include the reporting of negative findings.

IMM provides a new platform for all researchers, scientists, scholars, students to publish their research work and update the latest research information.Integrative Molecular Medicine publishes research articles as full-length research papers and short reports. In addition, the journal publishes editorials and review articles in innovative formats that target a broad and non-specialized audience.

Journal will accept article from the following topics are integrative medical fields including biochemistry, molecular and cell biology, biotechnology, genetics, physiology, endocrinology, signal transduction, cell proliferation, differentiation and development, stem cells and regenerative medicine apoptosis, gene expression, pathology, metabolic disease, genomics, transcriptomics, proteomics, metabolomics of disease, systems medicine, brain disease, cardiovascular biology, diabetes, obesity, osteoporosis, nutrition, pharmacology, toxicology, cancer biology and oncology, epidemiology, genetic medicine, and other medicine-related topics.

IMM welcomes direct submissions of manuscripts from authors. You can submit your manuscript to: submissions@oatext.com; alternatively to: yamaguchi@oatext.com

I graduated as an MD at Lviv State Medical University (Ukraine) in 1983 with a great passion to become a surgeon in oncology. Thinking that a PhD in experimental oncology would help to realize my dream, I obtained my doctorate at the Institute of Experimental Oncology, National Academy of Sciences of Ukraine in 1987. A fellowship from the International Agency for Research on Cancer (IARC) took me even further from clinical oncology and also from Ukraine. I arrived in London on the first wave of perestroika and began my post-doctoral training in Jim Woodgett's laboratory at the Ludwig Institute for Cancer Research (UCL Branch). Subsequently, I worked in Mike Waterfield's laboratory at the same Institute studying signal transduction via the PI3 kinase pathway. In 1996, I started my own group at the Ludwig Institute for Cancer Research, focusing on the regulation of growth via the S6 kinase pathway. Since 2003, I have been a Professor in the Department of Biochemistry at UCL now renamed Structural and Molecular Biology, where I have an active research group working on signal transduction and cellular metabolism in health and disease. I have a strong research (113 papers in peer-reviewed journals, H-Index 52) and patent (10 world-wide patents) portfolio and run two drug discovery programs aimed at developing small molecule inhibitors, targeting ribosomal S6 kinase and Aurora A kinase.

Dr. Alvarez, a native of Argentina, joined CTCA in October 2014 to lead the companys global focus on cancer research. He is internationally known for his contribution to breast cancer multidisciplinary management, inflammatory breast cancer, and discovery and monitoring of minimal residual disease in solid tumors. As a medical oncologist, he has focused his clinical career the past two decades on treating patients with the most difficult cases of breast cancer. Prior to joining CTCA, Dr. Alvarez served for five years as an Assistant Professor in the University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology, Division of Cancer Medicine in Houston, Tx. He also served as Assistant Professor at The Morgan Welch Inflammatory Breast Cancer Research Program. His additional experience includes teaching at the Department of Pathology and the Department of Internal Medicine, Universidad Nacional de La Plata, Argentina. He served as Chief, Oncology Section, Hospital Ramon Carrillo - San Carlos de Bariloche, Rio Negro, Argentina, and Instructor, Oncology Consultants P.A., Houston, Tx. He was Secretary of Clinical Oncology Section, School of Oncology, Fundacion Jose Maria Mainetti, Centro Oncologico de Excelencia, Gonnet, Argentina; and Member, Centro Oncologico de Excelencia, Gonnet.

Dr. Alvarez received his medical degree from Universidad Nacional de La Plata - Facultad de Medicina, Argentina. He completed his residency in internal medicine and medical oncology at Centro Oncologico de Excelencia - Gonnet, Argentina. Following completion of his medical oncology training, he pursued additional training in Clinical Pathology to further study molecular diagnostic and serve as Instructor at the Pathology Department with Dr. Pedro Laguens at the Universidad Nacional de La Plata. He also participated in multiple research activities and attended multiple grand rounds with Professors Jose Maria Mainetti and Alberto Luchina, and with several others became leaders in Argentinean oncology. Following his training in Argentina, he moved to Houston to pursue a medical residency in internal medicine at The University of Texas at Houston, and completed a fellowship in hematology and oncology at The University of Texas MD Anderson Cancer Center, Houston, TX. He earned a masters degree in cancer biology from the Graduate School of Biomedical Sciences at Houston. Dr. Alvarez has received numerous professional awards for his work in cancer research, including T-32 NIH CA009666 in 2006, Award of Excellence in Cancer Research by Texas Medical Society of Oncology in 2008, and the Susan Papizan Dolan Fellowship in Breast Cancer Research in 2008. He has participated in nearly $5 million in research grants and contracts with multiple clinical studies, including several Phase II Investigator Initiated Studies, since 2009 alone.

In 2014, he was Principal Investigator in a study related to monitoring minimal residual disease in locally advanced breast cancer and inflammatory breast cancer by detecting circulating tumor cells. The goal of this study, funded by Sister Institution Fund Network as part of the Global Academy Program Department at MD Anderson, is to identify molecular markers of breast cancer tumor recurrence. This clinical trial is currently active in the U.S., as well as in five academic Institutions across the world, including: INCan in Mexico, INEM in Peru, Clnica Alemana in Santiago de Chile, Barretos Hosptial in Brasil, and University of Oslo in Norway. Dr. Alvarez has authored more than 50 articles, abstracts and book chapters and is a frequent presenter at international oncology conferences. His professional memberships include: American Society of Clinical Oncology (ASCO,) American College of Physicians (ACP), American Society of Hematology (ASH), American Association of Cancer Research (AACR), and the Society of Clinical Research Associates (SOCRA). He was a founding member of Grupo de Estudio Tratamiento e Investigacion del Cancer del Sur (GETICS) in Argentina in 1996.

Hiromichi Nakadate Evrim Kurtoglu Shota Shirasaki Shigeru Aomura

Research Article-Integrative Molecular Medicine (IMM)

August 06, 2016

Taishi Koganemaru Koji Hori Misa Hosoi Kimiko Konishi Mitsugu Hachisu Hiroi Tomioka Masayuki Tani Yuka Kitajima Atsuko Inamoto

Case Report-Integrative Molecular Medicine (IMM)

August 09, 2016

Margaret Simonian

Editorial-Integrative Molecular Medicine (IMM)

August 09, 2016

Koji Wakame Akifumi Nakata Keisuke Sato Takehito Miura Anil.D.Kulkarni Marie-Francoise Doursout Alamelu Sundersan Ken-Ich Komatsu

Research Article-Integrative Molecular Medicine (IMM)

August 10, 2016

Veronica J. James Mark McGovern Peihong Wu Boyang Chang Yankeng Wu

Mini Review-Integrative Molecular Medicine (IMM)

August 18, 2016

Josh Hiller Celeste Vallejo Leo Betthauser James Keesling

Research Article-Integrative Molecular Medicine (IMM)

August 19, 2016

Gregory Lee

Research Article-Integrative Molecular Medicine (IMM)

August 25, 2016

Yoko Takai Asuka Matsuo Zhiwei Qiao Tadashi Kondo

Research Article-Integrative Molecular Medicine (IMM)

August 26, 2016

Oxenkrug G Cornicelli J van der Hart M Roeser J Summergrad P

Research Article-Integrative Molecular Medicine (IMM)

August 29, 2016

Cristina Daneri-Becerra Mario D. Galigniana

Research Article-Integrative Molecular Medicine (IMM)

August 22, 2016

Nepton Sheik Khoni GhazalehShoja E Razavi Himakshi Sharma

Research Article-Integrative Molecular Medicine (IMM)

August 22, 2016

Charles J. Malemud

Research Article-Integrative Molecular Medicine (IMM)

September 05, 2016

Nepton Sheik Khoni Abdul Rahman El Kinge Abdul Rahman El Kinge

Perspective-Integrative Molecular Medicine (IMM)

August 30, 2016

Akio Sugitachi Naoko Takahashi Yoshimori Takamori

Research Article-Integrative Molecular Medicine (IMM)

May 12, 2016

Alexander P Lykov Elena P Trifonova Olga V Sazonova Elena V Zonova

Research Article-Integrative Molecular Medicine (IMM)

May 14, 2016

Shigeru Aomura Hiromichi Nakadate Yuma Kaneko Akiyoshi Nishimura Remy Willinger

Research Article-Integrative Molecular Medicine (IMM)

May 18, 2016

Mitsumi Arito Hiroyuki Mitsui Manae S Kurokawa Kazuo Yudoh Toshikazu Kamada Hisateru Niki Tomohiro Kato

Research Article-Integrative Molecular Medicine (IMM)

May 26, 2016

Zen Kouchi

Research Article-Integrative Molecular Medicine (IMM)

May 27, 2016

Yoshimitsu Kiriyama Kunihiko Kasai Katsuhito Kino Hiromi Nochi

Research Article-Integrative Molecular Medicine (IMM)

June 10, 2016

Hisako Nakagawa Tadaaki Miyazaki

Research Article-Integrative Molecular Medicine (IMM)

June 13, 2016

Yoshikazu Hirasawa Hisayo Yokoyama Nooshin Naghavi Yoshihiro Yamashina Ryosuke Takeda Akemi Ota Daiki Imai Tomoaki Morioka Masanori Emoto Kazunobu Okazaki

Research Article-Integrative Molecular Medicine (IMM)

June 17, 2016

Toshihisa Ishikawa Masaharu Shinkai Takeshi Kaneko

Mini Review-Integrative Molecular Medicine (IMM)

June 22, 2016

Osman A Hamour Eman M.Fallatah Rawan O. Alshehri Zain A. Alshareef Halah F.AL-Enizi

Research Article-Integrative Molecular Medicine (IMM)

June 23, 2016

Kazuyuki Matsushima Mika Suematsu Chie Mifude Kuniyoshi Kaseda

Research Article-Integrative Molecular Medicine (IMM)

June 24, 2016

A. Espinosa-Jeffrey R. A. Arrazola B. Chu A. Taniguchi S. M. Barajas P. Bokhoor J. Garcia A. Feria-Velasco J. de Vellis

Research Article-Integrative Molecular Medicine (IMM)

June 25, 2016

Edna Aurelus

Research Article-Integrative Molecular Medicine (IMM)

July 07, 2016

Estela S. Estap

Commentary-Integrative Molecular Medicine (IMM)

July 07, 2016

Ricardo H. Alvarez Cancer Treatment Centers of America

Submission date: November 30, 2016 Publication date: January 31, 2017

Editor Affiliation: David W. Moskowitz MD FACP, Founder and CEO, GenoMed, Inc. (www.genomed.com)

Submission date: June 30, 2016 Publication date: August 03, 2016

Description of the Special Issue: It's widely agreed that molecular medicine will revolutionize the practice of medicine. Few people realize that it's long overdue. Linus Pauling and colleagues published "Sickle Cell Anemia, a Molecular Disease," in the November 1949 issue of Science, but the treatment for sickle cell disease remains unsatisfactory over 65 years later.

What has been holding up the medical revolution? Papers are solicited on this general topic. They may address any of the following topics, or another that the author feels is equally important:

1. Problems solving polygenic diseases 2. Is there a better approach to oncology? 3. Drug discovery and development in the 21st century 4. Shifting the healthcare industry to prevention: economic and legal challenges 5. The role of public health authorities 6. The role of the media 7. The role of investors

View original post here:
Molecular Medicine | Molecular Medicine Reports ...

The Department of Biochemistry and Molecular Biology is an integral part of the LSU Health in New Orleans, which includes the Schools of Allied Health, Dentistry, Graduate Studies, Medicine, and Nursing. The faculty within the Department have strong, diverse research interests including cancer molecular and cellular biology, neuropeptide and enzyme processing, protein biochemistry, gene promoter and expression analyses, molecular biology of aging, cardiac development, cancer genetics, and molecular epidemiology of cancer. The Department offers PhD and MD/PhD degrees. Students, postdoctoral research scientists, research faculty, and visiting faculty members make significant contributions to the Department's activities. Strong collaborations exist with Basic Science and Clinical researchers within the LSUHealth community, with research groups elsewhere on a national and international level, and with established and emerging biotechnology industry.

The Department is well-equipped with most modern biochemical equipment required for the analysis of nucleic acids and proteins, including a state-of-the-art microarray core, a DNA sequencing core, and preparative ultracentrifuges. The Department is also equipped with facilities for high-pressure liquid chromatography, fast protein liquid chromatography, fluorescent in situ hybridization, fluorescent activated cell sorting, and microinjection. The Health Sciences Center Core Laboratories contain facilities for oligonucleotide synthesis, peptide synthesis and microsequencing, mass spectroscopy, a fluorescence-activated cell sorter, and a phosphorimager. An Image Analysis facility includes a confocal microscope as well as a molecular modeling workstation.

The shop facilities of the Department contain all of the equipment needed for fabrication and repair of scientific equipment.

Together with the Neuroscience Center, the Department administers an extensive tissue culture facility, which provides sterile media preparation, long-term storage of cell lines in liquid nitrogen, and propagates cell lines. More than 100 cell lines are contained within the tissue culture liquid nitrogen banks.

In addition to its on-site library facilities, the Health Sciences Center belongs to a library consortium which provides inter-library loans of books and journals.

Sincerely, Arthur L. Haas, PhD Professor and Chairman

Continued here:
LSUHSC School of Medicine - Biochemistry and Molecular Biology

"One thing that was really great about the program was the combination of theory in the morning and practical work in the afternoon. This helped me keep everything in perspective and I found it highly motivating. In the lab I also learned so much; not only a lot of new techniques, but also how to approach and tackle a scientific question, and how to go about designing an experiment to specifically answer the question. Of course I had some idea about this before I began the program, but the lab placements enabled me to really practice this at a professional level. In my thesis right now, for example, I have a great deal of flexibility over the work Im doing, but I also have the chance to consistently check back with my supervisor to discuss next steps and possible future experiments. This combination of working independently but with support is essential for me to mature on the scientific level. In all, it also gives me the feeling that I am a researcher and not just another student."

Radwa Sharaf, graduate 2013, pursuing her PhD at Harvard soon.

Click here to find more about the International Master Program Molecular Medicine

Read the original post:
International Masters Program Molecular Medicine ...

The Graduate Training Program in Cellular and Molecular Medicine prepares scientists for laboratory research at the cellular and molecular level with a direct impact on the understanding, diagnosis, treatment and prevention of human diseases. The Ph.D. graduates of the Program will have a rigorous training in scientific research and a thorough knowledge of human biology and human diseases.

The CMM program grew out of a need for training at the interface between medicine and the traditional basic science disciplines. Rapid progress in cellular and molecular biology has strongly impacted clinical medicine, offering insights on fundamental causes of many diseases. Now new discoveries in the laboratory can be applied rapidly to the diagnosis, treatment and prevention of disease. This has been made possible by emerging technology that allows scientists to identify genetic and molecular defects causing or predisposing to disease. The trainees in this program are working precisely at this interface between science and medicine where they will be able to contribute to the long term well being of society.

Johns Hopkins University School of Medicine supports state of the art research and animal facilities, all on the East Baltimore campus.

Read more here:
Cellular and Molecular Medicine Graduate Program

From its home within the Department of Internal Medicine Section on Molecular Medicine, the Molecular Medicine and Translational Science program trains PhD students in research to better understand human diseases at a molecular level and translate that knowledge to improved diagnostics, treatment, and disease prevention. The MMTS program includes scientists from all major basic science and clinical programs at Wake Forest University and was one of the first established molecular medicine programs nationwide. Beginning in 2011, MMTS joined four other complementary PhD programs in the Wake Forest University Graduate Schools Molecular and Cellular Biosciences track, where combined expertise will be utilized to enhance the depth of student learning and discovery.

To learn more about the MMTS degree programs and their requirements, or aboutthe program's accomplished faculty, please follow the links on the left.

Program Directors and Contacts

Director: John S. Parks, PhD,Professor Department of Internal Medicine Molecular Medicine Phone: 336-716-2145 Email:jparks@wakehealth.edu

Co-Director: Robert N. Taylor, MD, PhD, Professor Department of Obstetrics and Gynecology Phone: 336-716-5451 Email: rtaylor@wakehealth.edu

Program Recruiter: Michael C. Seeds, PhD, Assistant Professor Department of Internal Medicine - Molecular Medicine Phone: 336-713-4259 E-mail: mseeds@wakehealth.edu

MMTS Policies and Procedures

MMTS Graduate Program Faculty

Molecular Medicine Journal Club

More here:
Molecular Medicine - Wake Forest Baptist Health